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Abstract
Background: Current guidelines for the management of bronchiectasis (BE) highlight the lack of evidence to
recommend mucoactive agents, such as hypertonic saline (HTS) and carbocisteine, to aid sputum removal as part
of standard care. We hypothesise that mucoactive agents (HTS or carbocisteine, or a combination) are effective in
reducing exacerbations over a 52-week period, compared to usual care.
Methods: This is a 52-week, 2 × 2 factorial, randomized, open-label trial to determine the clinical effectiveness
and cost effectiveness of HTS 6% and carbocisteine for airway clearance versus usual care - the Clinical and cost-
effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care (CLEAR) trial.
Patients will be randomised to (1) standard care and twice-daily nebulised HTS (6%), (2) standard care and
carbocisteine (750 mg three times per day until visit 3, reducing to 750 mg twice per day), (3) standard care and
combination of twice-daily nebulised HTS and carbocisteine, or (4) standard care. The primary outcome is the
mean number of exacerbations over 52 weeks. Key inclusion criteria are as follows: adults with a diagnosis of BE on
computed tomography, BE as the primary respiratory diagnosis, and two or more pulmonary exacerbations in the
last year requiring antibiotics and production of daily sputum.
Discussion: This trial’s pragmatic research design avoids the significant costs associated with double-blind trials
whilst optimising rigour in other areas of trial delivery. The CLEAR trial will provide evidence as to whether HTS,
carbocisteine or both are effective and cost effective for patients with BE.
(Continued on next page)
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Background
Background information
Bronchiectasis (BE) is a debilitating chronic illness
caused by irreversible dilatation, thickening and sac-like
formations in bronchial walls. Patients usually suffer
from a persistent cough, chronic daily sputum expector-
ation, recurrent chest infections and poor health-related
quality of life (HRQoL) [1, 2]. Current estimates suggest
around 5 in 1000 people in the UK have BE [3, 4] with
higher numbers of patients being diagnosed with BE due
to increased use of high-resolution computed tomog-
raphy (HRCT) [5]. Mortality in the 52 weeks after a BE-
related exacerbation is as high as 30% [6]. Morbidity is
also high and UK hospitals admission data indicate that
BE was the primary diagnosis in 1 in 1800 admissions,
with a sevenfold increase in hospital bed days needed for
treating BE in the first decade of the 21st century [7, 8].
Mucus hypersecretion is a clinical feature of BE. Air-
way mucosal infection often gives rise to inflammatory
mediators [9], including neutrophil-derived DNA and
filamentous actin, in addition to apoptotic cells and cel-
lular debris that may collectively increase mucus produc-
tion and viscosity. This mucus retention aids bacterial
infection that can lead to pulmonary exacerbations,
which further develops the “viscous cycle” of mucus re-
tention, infection, inflammation and tissue damage [10].
Mucoactive drugs target this cycle by potentially increas-
ing the ability to expectorate sputum and/or decrease
mucus hypersecretion. Mucoactive drugs are classified in
terms of their proposed primary mechanism of action:
expectorants induce mucus expulsion, mucoregulators
reduce mucus secretion, mucolytics decrease viscosity
and mucokinetics increase cilia activity.
Rationale for the study
The current guidelines indicate that mucoactive drugs
plus airway clearance may be considered to enhance
sputum expectoration in BE [11, 12] but Cochrane re-
views have shown that the evidence to support their use
is limited. Recent reviews have demonstrated that DNase
and mannitol do not reduce exacerbations [13, 14]. In
clinical trials, DNase increased exacerbations and
resulted in a significant decrease in lung function [15].
And, as shown in a recent overview of reviews, evidence
for the effectiveness of hypertonic saline (HTS) and car-
bocisteine is insufficient to recommend them within the
management of BE [16]. However, European Multicentre
Bronchiectasis Audit and Research Collaboration
(EMBARC)/UK Bronchiectasis Registry (BRONCH-UK)
data show that BE centres do prescribe mucoactive
drugs. This is important because adherence to therapy
in BE in general is low and decreases as the number of
prescribed medications increases, and is also related to
poorer patient outcomes, including the number of pul-
monary exacerbations and quality of life [17]. Therefore,
it is essential that only those drugs that are effective
should be prescribed for patients with BE. There are cost
considerations associated with mucoactive drugs, and
there is a risk of polypharmacy side effects.
Rationale for the interventions (use of HTS and
carbocisteine)
The physiological rationale for the use of HTS in BE is
based on its osmotic effects on the airway surface layer
that improves airway hydration and accelerates mucus
transportability, especially when combined with airway
clearance techniques (ACT). There have been multiple,
crossover studies exploring the use of HTS in BE [18–21]
that support these effects. The only long-term (1 year)
randomised, parallel-group study did not demonstrate
long-term efficacy of HTS (6%) compared to placebo [22],
but this “no effect” result may have been due to poor
study design or lack of power, the way in which exacerba-
tion data were collected, a true lack of effect of HTS on
mucus clearance or due to chance. Thus, the need to ex-
plore the use of HTS in BE remains, and patients and
practitioners need to have these important uncertainties
resolved. The physiological rationale for carbocisteine is
based on its ability to reduce the concentration of mucus
glycoprotein, which reduces the viscosity of mucus and fa-
cilitates expectoration. As with HTS, the evidence base for
carbocisteine in BE is poor. This contrasts to other re-
spiratory conditions, where there is relatively strong evi-
dence favouring both HTS and carbocisteine [22–24].
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Therefore, the CLEAR trial will answer important clinical
questions about whether similar benefits can be demon-
strated in BE by using a pragmatic design to explore the
specific effects of mucoactive agents, and directly support,
or refute, more targeted use of these drugs.
Rationale for comparator
In the CLEAR trial, the comparator will be standard
care. In the UK, standard care is defined by the British
Thoracic Society (BTS) guidelines for BE [25]. All sites
will be encouraged to follow these guidelines such that
all patients in the control group (as well as in the three
intervention groups) will be expected to have been pre-
scribed and taught ACT. If patients are not familiar with
ACT, they will be taught the active cycle of breathing
techniques [26].
Objectives
The primary objective of the CLEAR trial is to deter-
mine whether HTS (6%) and/or carbocisteine reduces
the mean number of exacerbations over 52 weeks. Sec-
ondary objectives are to determine whether HTS and/or
carbocisteine improve disease-specific HRQoL, reduce
time to next exacerbation, reduce number of days of an-
tibiotics for treatment of exacerbations, improve generic
HRQoL, are acceptable from a patient satisfaction per-
spective, are associated with adverse events (AEs) and
improve lung function over 52 weeks. The study will also
assess cost effectiveness and treatment adherence.
Study design
CLEAR is a multicentre, superiority, 2 × 2 factorial, ran-
domized, open-label trial in BE with a 52-week follow-
up period. Patients will be randomised (1:1:1:1 ratio) to
one of four groups: HTS alone, carbocisteine alone, HTS
and carbocisteine or standard care. Additionally, all pa-
tients will be followed up at 104 weeks to explore their
mucoactive drug use in the 52 weeks following the com-
pletion of the main trial. For the SPIRIT checklist,
please see Additional file 8.
Embedded sub-studies
There are three embedded sub-studies within the
CLEAR trial. The first aims to validate and measure the
sensitivity of the EMBARC definition of exacerbations in
BE (see Additional file 1). The second sub-study will
examine the use of a new home spirometer mySpiro-
Sense for remote monitoring (see Additional file 3). The
third will use Studies Within A Trial (SWAT) [27] to ex-
plore the effect of methods used to optimise recruitment
and retention (see Additional file 4). These sub-studies
will be reported separately from the main report for
CLEAR.
Methods/design
Study setting
The CLEAR sites will include at least 16 National Health
Service (NHS) hospitals in the UK with access to pa-
tients with BE managed according to BTS guidelines.
Sites will include those that are part of the BRONCH-
UK/or EMBARC research network [28], and additional
sites will be chosen from the Northern Ireland Clinical
research Network (NICRN)/National Institute for Health
Research Clinical Research Network (NIHR CRN)
portfolio if required. The current list of study sites is in
Additional file 5.
Internal pilot study
The main trial will be preceded by an 8-month internal
pilot study in 10 sites, which will follow the processes
described for the main trial with target recruitment of
60 patients. This internal pilot will be used to confirm
recruitment rates, protocol compliance and data collec-
tion methods.
Characteristics of participants
Patients will be eligible to participate in the CLEAR trial
if they fulfil the following inclusion criteria: diagnosis of
BE on computerised tomography (CT)/HRCT, BE as the
primary respiratory diagnosis, two or more pulmonary
exacerbations in the last year requiring antibiotics (in-
cluding patient-reported exacerbations), production of
daily sputum, stable for 14 or more days before first
study visit with no changes to treatment, willing to con-
tinue any other existing medication for chronic illness
throughout the study, and female participants must be
either surgically sterile, postmenopausal or agree to use
effective contraception during the treatment period of
the trial.
The exclusion criteria are as follows: < 18 years old,
cystic fibrosis (CF), chronic obstructive pulmonary dis-
ease (COPD), current smokers, female ex-smokers with
> 20 pack years and male ex-smokers with > 25 pack
years, forced expiratory volume in 1 s (FEV1) < 30%, if
being treated with long term macrolides on treatment
for < 1 month before joining study, regular isotonic sa-
line, HTS, carbocisteine or any mucoactive drugs taken
within the past 30 days, known intolerance or contra-
indication to HTS or carbocisteine, contraindications to
or special warnings against the use of carbocisteine (ac-
tive peptic ulceration, hereditary galactose intolerance,
Lapp-lactase deficiency, glucose-galactose malabsorp-
tion), unable to swallow oral capsules, women who are
pregnant or lactating, or participation in another clinical
trial of an investigational medicinal product (IMP)
within 30 days. Patients currently using mucoactive
drugs can be considered for the CLEAR trial if they stop
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these for at least 30 days before being assessed for
eligibility.
Screening and informed consent
Written informed consent will be obtained by the site
principal investigator or appropriately trained designee.
All interested individuals who are eligible using the
screening criteria will be given a participant information
sheet and allowed as much time as necessary to consider
the study. Informed consent will be obtained using
standard procedures (Additional files 6 and 7).
Intervention and comparator
The interventions and comparators are as follows:
Intervention 1: standard care and twice-daily nebulised
HTS (MucoClear 6%, PARI Pharma GmbH). Partici-
pants will be instructed to administer a 1 × 4 mL am-
poule twice daily for 52 weeks using the eFlow rapid
nebuliser and eTrack controller (PARI Pharma GmbH).
Intervention 2: standard care and carbocisteine (750 mg
three times per day until visit 3*, reducing to 750 mg
two times per day) over 52 weeks.
Intervention 3: standard care and combination of
twice-daily nebulised HTS (MucoClear 6%, PARI
Pharma GmbH). Participants will be instructed to ad-
minister a 1 × 4 mL ampoule twice daily for 52 weeks
using the eFlow rapid nebuliser eFlow rapid nebuliser
and eTrack controller (PARI Pharma GmbH). They will
also be given carbocisteine (750 mg three times per day
until visit 3*, reducing to 750 mg twice per day) over
52 weeks.
Comparator: standard care over 52 weeks. Patients in
the standard care group will use airway clearance
techniques in the management of their BE.
*Visit 3 occurs 8 weeks (±7 days) after the baseline
assessment).
Concomitant care
Sites in this study all follow BTS guidelines for manage-
ment of BE. Any prescribed medication deemed neces-
sary to provide adequate medical care to the patient is
permitted, other than as stated in the study exclusion
criteria. The use of mucoactive drugs/isotonic saline out-
side the allocated treatment is not permitted except for
short periods during exacerbations.
Treatment discontinuation
All patients allocated to a treatment group including
HTS 6% will complete a drug response assessment prior
to commencing HTS in accordance with a study-specific
guideline and if they do not pass this they will not con-
tinue on the study. Participants may withdraw from
treatment at any time, without providing an explanation,
or if discontinuation is considered by the medical team
to be in the best interests of the patient. Anticipated rea-
sons for withdrawal include intercurrent significant ill-
ness, occurrence of intolerable side effects, patient
request, protocol violations or decision that the study
drug should be discontinued on safety grounds. A par-
ticipant may be withdrawn from the study at the discre-
tion of the Investigator due to safety concerns.
Study drug accountability, compliance and adherence
Patients will be asked to return any unused HTS 6% am-
poules or carbocisteine at each study visit, to facilitate
drug accountability. Adherence to HTS will be moni-
tored utilising the eFlow nebuliser system with eTrack
controller (which records data on nebuliser usage in-
cluding frequency of use, dosage and maintenance). For
the two HTS groups (intervention groups), study visit
data from the eFlow nebuliser system with eTrack con-
troller will be transferred to a Qualcomm Life 2Net Hub
and subsequently to a secure Cloud-based platform.
These data will not be reviewed and analysed until the
end of the study, but will be checked weekly by a person
not involved in study delivery, to ensure that the eFlow
nebuliser system with eTrack controller is being used
correctly and data are being transferred correctly.
Outcomes
The primary outcome measure is the mean number of
exacerbations over 52 weeks after randomisation. Sec-
ondary outcome measures are disease-specific HRQoL
(respiratory symptoms of the domain of Quality of Life -
Bronchiectasis (QoL-B) [29]), time to next exacerbation,
number of days of antibiotics related to exacerbations,
generic HRQoL (Euroqol 5 dimensions 5 levels (EQ-5D-
5 L) [30]), measurement of health impairment using the
St Georges Respiratory Questionnaire (SGRQ) [2]),
health service use, quality-adjusted life years (QALYs),
patient preferences for treatment, adverse events, lung
function and adherence to trial treatment over 52 weeks.
Spirometry
All patients will be provided with a hand-held spirom-
eter (mySpiroSense; PARI GmbH) to complete regular
lung function tests at home (Additional file 3) and to
record lung function at the beginning and end of an ex-
acerbation. The mySpiroSense spirometer is a digital,
self-calibrating instrument. Patients will bring the
mySpiroSense to study visits so that its data can be
imported to computers on site. The spirometry data can
be viewed using the SpiroSensePro software and add-
itionally the database can be transformed and exported
as a Microsoft Excel (.xls) file and viewed.
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Exacerbation management
During the treatment period, if patients have symptoms
of exacerbation for 48 h or feel that they require anti-
biotic therapy, they will be asked to call the study team.
Exacerbations will be defined as per the recent consen-
sus [31]. A comprehensive exacerbation management
plan is detailed in Additional file 2. In general, patients
will have rescue medication at home to facilitate man-
agement of exacerbations remotely. The trial will use an
adjudication panel to categorise exacerbations.
Respiratory and Systemic Symptoms Questionnaire (RSSQ)
A member of the research team will administer the
RSSQ questionnaire at each study visit to capture
changes in the predefined signs and symptoms relative
to normal day-to-day fluctuations [32]. It covers a range
of patient-reported outcomes relating to cough, sputum,
haemoptysis, dyspnoea, lethargy, sinuses, appetite and
fever [33]. Modified versions of the RSSQ will be used to
capture details of potential exacerbations reported be-
tween study visits.
Health-related quality of life (HRQoL) questionnaires
Three HRQoL questionnaires will be used: QoL-B,
SGRQ and EQ-5D-5 L. The QoL-B assesses symptoms,
functioning and HRQoL specific to patients with BE [29,
34, 35]. The SGRQ measures health impairment [2, 34].
The EQ-5D-5 L provides a simple descriptive profile and
a single index value for health status [30].
Health Service Use Questionnaire
A questionnaire and log will be used to capture partici-
pants’ health service use over the study period, including
details of medications prescribed (including antibiotics).
This will be used for the health economic analysis.
Treatment Satisfaction Questionnaire for Medication
At each study visit, participants (except those rando-
mised to the standard care group) will be asked what
they think about the effectiveness, side effects and con-
venience experienced when using the medication over
the last 2–3 weeks, or since they last used it. Patients
assigned to the group combining HTS and carbocisteine
(intervention group 3) will be asked to complete separate
questionnaires for each treatment.
Schedule of assessments
All patients will be evaluated during the study according
to the schedule of assessments outlined in Fig. 1 and
Table 1. See also Additional file 8 for the SPIRIT
checklist.
Sample size
The required sample size is 380 patients including the
internal pilot. Based on the primary outcome of mean
exacerbations during 52 weeks and a pooled standard
deviation of 0.9 exacerbations [36], and assuming the
mean number of exacerbations in the control group is
0.7, 216 patients would be sufficient to detect a mean
difference in exacerbation rate between groups of 0.4,
with 90% power and at the 5% significance level. To
allow for a potential interaction between the two inter-
ventions, 50% inflation has been included, requiring 324
patients. Further, compensating for 15% dropout gives
the total required of 380 patients (95 in each of the four
groups). In regard to secondary outcomes, this sample
size would provide over 90% power to detect a minim-
ally important difference of 8 points for the QoL-B scale
(standard deviation of 18) at the 5% significance level
[18, 29] and a 75% increase in median time to exacerba-
tion at 98% power. It would also be sufficient to detect a
medium effect size for the other secondary outcomes, at
95% power and 5% level of significance.
Recruitment
Potential participants may be identified through the
EMBARC and BRONCH-UK registries at each of the
participating sites, through referrals or while in clinics.
Twitter and Facebook accounts (https://twitter.com/
TrialCLEAR; https://www.facebook.com/TrialCLEAR/)
are being used to encourage engagement and awareness
of the trial. The study team will have regular teleconfer-
ences with sites to review screening and recruitment fig-
ures and resolve any issues.
Randomisation and blinding
Treatment allocation at each site will be assigned using
a concealed automated randomisation process provided
by an external organisation. Participants who give their
consent will be allocated using a fixed block size to one
of the four groups (three intervention groups or one
standard care group) in a 1:1:1:1 ratio using a central
randomisation system. Randomisation will be stratified
by (1) site, (2) exacerbations in the last year (2–3 times,
> 3 times) (to minimise baseline imbalances in antibiotic
use) and (3) current use of macrolides (yes, no). The trial
is open label, and patients, investigators and outcome as-
sessors will be aware of treatment allocation.
Data collection, quality and procedures
All data collected during study visits and telephone calls
with each patient will be recorded in the CLEAR source
documents/electronic case report form (CRF). If a par-
ticipant withdraws during their first year on the study,
they will be asked to attend follow-up visits for collec-
tion of outcome data. If they do not wish to attend
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outcome data collection, permission will be sought to
access medical notes for collection of data relevant to
the trial e.g. the use of antibiotics. If a participant with-
draws from all parts of the study, their anonymised data
(recorded up to the point of withdrawal) will be included
in the study analysis. All patient data will be
anonymised.
Data management
Trial data will be entered onto the electronic case report
form (CRF) on a clinical trial database (MACRO) by del-
egated site personnel and processed electronically as per
the Northern Ireland Clinical Trial Unit’s (NICTU)
standard operating procedures (SOPs) and the study-
specific data management plan (DMP). Data queries will
be “raised” electronically using MACRO where clarifica-
tion from site staff is required for data validations or
missing data. Site staff will respond electronically to data
queries, ensuring that necessary amendments are made
to the clinical trial database.
Statistical analysis
Baseline characteristics, follow-up measurements and
safety data will be described using descriptive summary
measures depending on the scale of measurement. The
primary analysis will be conducted on a modified
intention-to-treat basis consisting of randomised partici-
pants with data from at least one post-baseline efficacy
Fig. 1 Study schematic. BE, bronchiectasis; BRONCH-UK, UK Bronchiectasis Registry; EMBARC, European Multicentre Bronchiectasis Audit and
Research Collaboration; NIHR, National Institute for Health Research; NICRN, Northern Ireland Clinical research Network; HTS, hypertonic saline;
QoL-B, Quality of Life - Bronchiectasis; HRQoL, health-related quality of life; QALY, quality-adjusted life year; SGRQ, Saint George’s
Respiratory Questionnaire
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assessment. A per-protocol analysis may also be con-
ducted to compare treatment groups. Groups will be
compared for the primary outcome (number of exacer-
bations over 52 weeks) and antibiotic use (number of
days of antibiotic use over 52 weeks) using negative bi-
nomial regression adjusted for baseline characteristics
and other covariates. The QoL-B and other continuous
outcomes will be compared between groups using ana-
lysis of covariance (ANCOVA) adjusting for baseline
characteristics and other covariates. The trial’s 2 × 2 fac-
torial design permits the separate testing of the effects of
HTS and carbocisteine on HRQoL and the detection of
any interaction between them. These tests will be imple-
mented using three contrasts (representing HTS, carbo-
cisteine and the interaction) in the models. For time to
next exacerbation, Kaplan-Meier curves will be prepared
and the log-rank test applied to compare the groups.
Analyses will be two-sided and tested at an a priori sig-
nificance level of p = 0.05. The primary time point has
been defined as 52 weeks after randomisation. There is
no adjustment for multiple testing at the different time
points, because the primary outcome has been pre-
defined and prioritised. Standard approaches will be
used to detect missing data.
Health economics evaluation
A within-trial economic evaluation will assess the cost-
effectiveness of the four treatment options at 26 and 52
weeks from the perspective of the NHS and Personal So-
cial Services. A within-the-table analysis will be per-
formed, treating the four groups in the factorial design
as mutually exclusive treatments. Economic outcomes
will then be estimated and presented separately for each
treatment option so that the effect of any interactions
can be seen directly. We will estimate the cost per
QALY gained, the cost per exacerbation avoided and the
net benefit (NB) in each of the treatment groups. Re-
gression analysis with an interaction term will be per-
formed, as a robustness check and to control for
baseline covariates. Participants’ health service use and
prescriptions (both related and unrelated to their BE)
will be prospectively collected from baseline to 52 weeks
using logs and questionnaires administered as per
Table 1. Costs will be calculated by attaching appropri-
ate unit costs from national sources. QALYs will be cal-
culated using responses on the EQ-5D-5 L over the
study period. Uncertainty surrounding the incremental
cost-effectiveness ratios will be summarised in cost-
effectiveness acceptability curves showing the probability
of the therapeutic strategies being cost effective at differ-
ent threshold levels of willingness to pay per QALY and
per exacerbation avoided. Sensitivity will be analysed to
explore the impact on cost effectiveness of variations in
Table 1 Schedule of assessments
*It is planned that week 104 data will be collected from the European
Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) or UK
Bronchiectasis Registry (BRONCH-UK). If this is not possible, the participant will
be asked to visit the research site for the data to be collected. BE,
bronchiectasis; QoL-B, Quality of Life - Bronchiectasis; SGRQ, Saint George’s
Respiratory Questionnaire; EQ-5D-5L, EuroQoL five dimension five
level questionnaire
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key parameters. Detailed statistical and health economic
analysis plans will be finalised before the commence-
ment of analysis.
Monitoring arrangements
The trial will be monitored on site in accordance with
the trial monitoring plan. This will be an on-going activ-
ity from the time of initiation until trial close-out and
will comply with the principles of Good Clinical Practice
(GCP) and applicable regulatory requirements. The Data
Monitoring and Ethics Committee (DMEC) will safe-
guard the rights, safety and wellbeing of trial partici-
pants, monitor data and make recommendations to the
Trial Steering Committee (TSC) on whether there are
ethical or safety reasons why the trial should not con-
tinue. They will monitor the overall conduct of the study
to ensure the validity and integrity of the study findings,
and will meet annually. The DMEC will comprise inde-
pendent members with at least one statistician and two
respiratory specialists. A DMEC charter will detail the
terms of reference of the DMEC, including membership
and roles and responsibilities.
Adverse events
All adverse events (AEs) that are directly observed and
spontaneously reported by the patient will be recorded
on their CRF. Signs and symptoms of pulmonary exacer-
bations collected as outcomes of the trial will not be re-
ported as AEs. Therefore, if a patient requires
hospitalisation or prolongation of existing hospitalisation
as a result of an exacerbation, this will not be reported
as a serious adverse event (SAE). The Principal Investi-
gator or designee will assess severity, seriousness, causal-
ity, severity and expectedness for each AE and these will
be reported in keeping with regulatory requirements.
End of study
The main trial analysis will be conducted at 52 weeks;
however, the formal end of the study will be at the end
of the 104-week follow up to establish mucoactive drug
use in participants. The trial will be stopped prematurely
if mandated by the responsible Research Ethics Commit-
tee (REC), Medicine and Healthcare Products Regulatory
Agency (MHRA), Sponsor (e.g. following advice from
the TSC based on recommendations from the DMEC)
or if funding for the trial ceases. The REC that originally
gave a favourable opinion of the trial and the MHRA
who issued the Clinical Trial Authorisation (CTA) will
be notified in writing once the CLEAR trial has been
concluded or if it is terminated early.
Site training
All sites will undertake comprehensive site initiation
visits (SIV). PARI or the research team will provide
training to sites on the eFlow nebuliser system with
eTrack controller, SpiroSensePro and mySpiroSense
spirometer. Follow-up refresher training will be delivered
prior to the first patient’s first visit, and sites will be ad-
vised to send questions to the research team at any time.
A document containing frequently asked questions will
be maintained and circulated to sites, along with a regu-
lar newsletter detailing any updates and news on the
trial, such as recruitment milestones.
Trial management arrangements
Trial-specific oversight committees will be convened for
the CLEAR trial. These will include a Trial Management
Group (TMG), TSC and DMEC. The NICTU will facili-
tate the setting up and the co-ordination of these com-
mittees. All study amendments will be managed by the
NICTU and communicated appropriately.
Patient and public involvement
Service users are involved in the CLEAR trial in both a
consultative and collaborative capacity and have influ-
enced this protocol, including the choice of interventions
and outcomes to measure. The Chair of Primary Ciliary
Dyskinesia Family Support Group UK and a BE carer is
a co-applicant on the trial grant and a member of the
TSC. The study is registered with the INVOLVE open-
access database, which registers research healthcare pro-
jects involving members of the public as partners in the
research process.
Data sharing and data access
Requests for data sharing will be reviewed on an individ-
ual basis by the Chief Investigator (CI) and TMG. Fol-
lowing the publication of the trial’s main outcomes,
there may be scope to conduct additional analyses on
the data collected. In such instances, formal requests for
data will be made to the CI for discussion with the
TMG. If publications might arise from such analyses,
those responsible will provide the CI with a copy of the
intended manuscript for approval prior to submission to
a journal.
Discussion
CLEAR is a pragmatic effectiveness trial. It was designed
as an open-label trial (in preference to a blinded trial)
because of factors including the prohibitive cost and
feasibility of conducting a trial with blinded patients,
practitioners and/or outcome assessors. There is increas-
ing support for trials to use more pragmatic research de-
signs [37], especially in therapy trials where blinding is
not feasible [38] or practical and when the funding re-
quired to implement blinded trials could be better used
to optimise rigour in other areas of trial delivery (Anand
R, Norrie J, Bradley JM, McAuley DF, Clarke M: Fool’s
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gold? Why double blind trials are not always best, sub-
mitted). The CLEAR trial also has added value through
the embedding of low-cost sub-studies to resolve im-
portant uncertainties about trial methods [27].
The findings of the CLEAR trial will be published in a
peer-reviewed journal and will help inform national and
international guidelines on the use of HTS and carbocis-
teine as mucoactive drugs for treatment of BE. A lay
person’s summary will be sent to local and national pa-
tient support and liaison groups, including the European
Lung Foundation BE Patient Advisory Group and the
British Lung Foundation as well as similar organisations
in devolved nations of the UK. A report of the study
findings will be provided for the INVOLVE registry. Fol-
lowing journal publication, key findings will be posted
on institutional websites that are freely available to the
general public and others.
In summary, HTS and carbocisteine are the two most
commonly used mucoactive agents in BE, being pre-
scribed to up to 20% of patients but without a solid
evidence-base for their effectiveness. The CLEAR trial
will demonstrate whether these one-in-five patients with
BE are being asked to take burdensome medications that
are ineffective or, if effective, whether more consider-
ation needs to be given to prescribing these medications
to the remaining 80% of patients with BE.
Trial status
Recruitment to the CLEAR trial started in July 2018 and
at the time of proof reading of this manuscript (Decem-
ber 2019), 130 patients had been recruited, with recruit-
ment aimed to be completed by August 2020. Analysis
will begin after recruitment and follow up are completed
and the database has been cleaned and locked. The
current protocol version is 3.0 (14/05/2018).
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-019-3766-9.
Additional file 1. Validity and sensitivity of the EMBARC definition for
exacerbations in bronchiectasis: a sub-study within the CLEAR trial.
Additional file 2. Exacerbation management guideline.
Additional file 3. Spirometry sub-study.
Additional file 4. Optimising recruitment and retention: implementing
studies within a trial (SWAT) in the CLEAR trial.
Additional file 5. List of Investigative Sites.
Additional file 6. Informed Consent Form.
Additional file 7. Patient Information Sheet.
Additional file 8. SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents*.
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